Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (GB:0JYL)
LSE:0JYL
Holding GB:0JYL?
Track your performance easily
0JYL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.06 - $11.24
Previous Close$1.61
Volume1.02K
Average Volume (3M)3.65K
Market Cap
$104.66M
Enterprise Value$96.58M
Total Cash (Recent Filing)$64.70M
Total Debt (Recent Filing)$56.63M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,084,038
10 Day Avg. Volume2,027
30 Day Avg. Volume3,649
Standard Deviation0.28
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.94
Price to Sales (P/S)2.97
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$6.40Price Target Upside298.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Marinus News
PremiumPre-Earnings
Is MRNS a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Commercial StrategyExpected commercial synergies with Ztalmy.
Patient EnrollmentPatient enrollment is now complete in the TrustTSC trial, with the last patient visit expected in September, and top-line data in the first half of 4Q24.
Trial DesignThe trial design has been adjusted to increase the chance of success by lowering somnolence rates and controlling the placebo response.
Bears Say
Clinical TrialsThe trial is enrolling more severely affected patients, which could pose an added risk.
Commercial OpportunityEven though the RAISE study will go on to a final analysis, the implications of the interim miss are that even a statistical win at the full analysis would not yield a significant commercial opportunity.
Financial PerformanceMarinus holds more debt (~$95M, including RIF) than cash with OpEx ~$115/yr thru '26 offset by $35M to $50M in Ztalmy's CDD revenues ('24 to '26), before Ztalmy in TSC's early '26 launch can begin to work towards breaking even in 2H'27, >two years from now.
---
0JYL FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest share price was $1.06 and its highest was $11.24 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is Nov 05, 2024 which is in 41 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on Aug 13, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.04.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -$0.43.
How many shares outstanding does Marinus have?
Marinus has 55,084,038 shares outstanding.
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went down -1.073%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is Woodline Partners LP. It holds Marinus’s shares valued at 5M.
---
Marinus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.40 (298.75% Upside)
$6.40 (298.75% Upside)
Blogger Sentiment
Bullish
GB:0JYL Sentiment 66%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.21%
12-Months-Change
Fundamentals
Return on Equity
-2986.55%
Trailing 12-Months
Asset Growth
-56.72%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
0JYL Earnings Call
Q2 2024
0:00 / 0:00
---
0JYL Stock 12 Month Forecast
Average Price Target
$6.40
▲(298.75% Upside)
Technical Analysis
Marinus
―
Karyopharm Therapeutics
―
Axsome Therapeutics
―
Xeris Pharmaceuticals
―
BioVie
―
Best Analysts Covering 0JYL
1 Year
1 Year Success Rate
12/25 ratings generated profit
1 Year Average Return
-6.86%
reiterated a buy rating 14 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of -6.86% per trade.
---